A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine
The purpose of this study is to compare the effectiveness of treatment with BMS-232632 to that of efavirenz (EFV) when both are used with zidovudine (ZDV) and lamivudine (3TC).
|Study Design:||Masking: Double-Blind
Primary Purpose: Treatment
|Official Title:||A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 With Efavirenz; Each in Combination With Fixed Dose Zidovudine-Lamivudine|
|Study Start Date:||February 2001|
|Study Completion Date:||April 2003|
|Primary Completion Date:||April 2003 (Final data collection date for primary outcome measure)|
This is a multinational, 2-arm study. Patients in 1 arm receive BMS-232632 plus EFV placebo capsules. Patients in the other arm receive EFV plus BMS-232632 placebo. Both arms also receive a fixed dose of ZDV-3TC.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00013897
Show 99 Study Locations